Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

15 May 2021: Database Analysis

H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro

Min Luo 1ABCE , Yao Xiong 2BCE , Yan Lin 1CD , Rong Liang 1CD , Yongqiang Li 1D , Lianying Ge 3ADE*

DOI: 10.12659/MSM.930215

Med Sci Monit 2021; 27:e930215

Figure 3 Hepatocellular carcinoma cell line screening. Hepatocellular carcinoma cell lines HepG2, SMMC-7721, and Huh-7 were screened for HHLA2 expression. HL-7702 cells were used as normal liver cells. (A) Relative HHLA2 mRNA levels based on qRT-PCR assay. * P<0.05. (B) Western blot analysis of HHLA2 protein. β-tubulin was used as an endogenous control. (C) HepG2 cells were transfected with lentivirus expressing 1 of 3 shRNAs targeting HHLA2 or a control shRNA, and HLLA2 knockdown efficiency was measured after 48 h by western blotting. HepG2+shRNA 1 caused the strongest knockdown (*** P<0.001). Actin was used as an endogenous control.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750